Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2019 3
2020 2
2021 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Quality of life assessment of cell-free and concentrated ascites reinfusion therapy during initial treatment for advanced ovarian cancer: A prospective cohort study.
Yamamoto K, Nagao S, Tsu T, Matsushima T, Ishido Y, Narita M, Suzuki K, Nakazawa H, Shibutani T, Jimi T, Yano H, Kitai M, Shiozaki T, Matsuoka K, Yamaguchi S. Yamamoto K, et al. Among authors: matsuoka k. J Obstet Gynaecol Res. 2021 Apr;47(4):1536-1543. doi: 10.1111/jog.14670. Epub 2021 Jan 20. J Obstet Gynaecol Res. 2021. PMID: 33469981
A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Nagao S, Kogiku A, Suzuki K, Shibutani T, Yamamoto K, Jimi T, Kitai M, Shiozaki T, Matsuoka K, Yamaguchi S. Nagao S, et al. Among authors: matsuoka k. J Ovarian Res. 2020 Feb 7;13(1):14. doi: 10.1186/s13048-020-0617-y. J Ovarian Res. 2020. PMID: 32028974 Free PMC article. Clinical Trial.
Dose-dense paclitaxel and carboplatin vs. conventional paclitaxel and carboplatin as neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: a retrospective study.
Shibutani T, Nagao S, Suzuki K, Kaneda M, Yamamoto K, Jimi T, Yano H, Kitai M, Shiozaki T, Matsuoka K, Sudo T, Yamaguchi S. Shibutani T, et al. Among authors: matsuoka k. Int J Clin Oncol. 2020 Mar;25(3):502-507. doi: 10.1007/s10147-019-01567-y. Epub 2019 Nov 1. Int J Clin Oncol. 2020. PMID: 31677021